Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5791 AL 5805

The essential dialogue: a Norwegian study of art communication in mental health care

Ingeberg MH, Wikstrøm BM, Berg A.

J Psychosoc Nurs Ment Health Serv. 2012 Aug;50(8):22-30. doi: 10.3928/02793695-20120703-01. Epub 2012 Jul 15.

Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY)

Waldorff FB, Buss DV, Eckermann A, Rasmussen ML, Keiding N, Rishøj S, Siersma V, Sørensen J, Sørensen LV, Vogel A, Waldemar G.

BMJ. 2012 Jul 17;345:e4693. doi: 10.1136/bmj.e4693.

"Keep up the good work"! A case study of the effects of a specific cognitive training in Alzheimer's disease

Cavallo M, Cavanna AE, Harciarek M, Johnston H, Ostacoli L, Angilletta C.

Neurocase. 2013;19(6):542-52. doi: 10.1080/13554794.2012.701643. Epub 2012 Jul 24.

Solving the puzzle of Alzheimer disease

Uriri-Glover J, McCarthy M, Cesarotti E.

Nurse Pract. 2012 Sep 10;37(9):20-7; quiz 27-8. doi: 10.1097/01.NPR.0000418381.60864.68.

Dying other, dying self: creating culture and meaning in palliative healthcare

McCann CJ, Adames HY.

Palliat Support Care. 2013 Aug;11(4):289-93. doi: 10.1017/S1478951512000557. Epub 2012 Aug 1.

[Dementia guidelines: what should come to general practice--an interdisciplinary consensus of physicians in private practice]

Riepe MW, Fellgiebel A; DEGAM, DGN, DGPPN.

Dtsch Med Wochenschr. 2012 Jul;137(30):1499-504. doi: 10.1055/s-0032-1305171. Epub 2012 Aug 6.

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM.

Arch Neurol. 2012 Nov;69(11):1430-40. doi: 10.1001/archneurol.2012.2194.

Assessing the impact and social perception of self-regulated music stimulation with patients with Alzheimer's disease

Lancioni GE, O'Reilly MF, Singh NN, Sigafoos J, Grumo G, Pinto K, Stasolla F, Signorino M, Groeneweg J.

Res Dev Disabil. 2013 Jan;34(1):139-46. doi: 10.1016/j.ridd.2012.07.026. Epub 2012 Sep 1.

The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results

Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E.

J Neurol Sci. 2012 Nov 15;322(1-2):96-101. doi: 10.1016/j.jns.2012.07.003. Epub 2012 Sep 7.

NAPA 2.0: the next giant leap

Khachaturian AS, Paul SM, Khachaturian ZS.

Alzheimers Dement. 2012 Sep;8(5):379-80. doi: 10.1016/j.jalz.2012.08.002.

Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year

Winchester J, Dick MB, Gillen D, Reed B, Miller B, Tinklenberg J, Mungas D, Chui H, Galasko D, Hewett L, Cotman CW.

Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):96-103. doi: 10.1016/j.archger.2012.06.016. Epub 2012 Sep 5.

Technology-based orientation programs to support indoor travel by persons with moderate Alzheimer's disease: impact assessment and social validation

Lancioni GE, Perilli V, O'Reilly MF, Singh NN, Sigafoos J, Bosco A, Caffò AO, Picucci L, Cassano G, Groeneweg J.

Res Dev Disabil. 2013 Jan;34(1):286-93. doi: 10.1016/j.ridd.2012.08.016. Epub 2012 Sep 14.

[Consensus 2012--diagnosis and treatment of patients with dementia in Switzerland]

Monsch AU, Büla C, Hermelink M, Kressig RW, Martensson B, Mosimann U, Müri R, Vögeli S, von Gunten A; Alzheimer Forum Schweiz.

Praxis (Bern 1994). 2012 Sep 19;101(19):1239-49. doi: 10.1024/1661-8157/a001085.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias